Real-world evidence for regulatory decision-making: updated guidance from around the world

被引:2
|
作者
Burns, Leah [1 ]
Le Roux, Nadege [2 ]
Kalesnik-Orszulak, Robert [3 ]
Christian, Jennifer [4 ]
Dudinak, Jennifer [5 ]
Rockhold, Frank [6 ]
Khozin, Sean [7 ]
O'Donnell, John [1 ]
机构
[1] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ 08540 USA
[2] Bristol Myers Squibb, Regulatory Intelligence, Boudry, Switzerland
[3] Bristol Myers Squibb, Global Regulatory Sci, Princeton, NJ USA
[4] Target RWE, Durham, NC USA
[5] Bristol Myers Squibb, Global Regulatory Sci, Summit, NJ USA
[6] Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[7] MIT, Cambridge, MA USA
关键词
real-world evidence; real-world data; regulatory decision-making; real-world evidence regulatory frameworks; real-world data quality methods; real-world study methods; health technology assessment; SCIENTIFIC ADVICE;
D O I
10.3389/fmed.2023.1236462
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leveraging the value of real-world evidence (RWE) to make informed regulatory decisions in the field of health care continues to gain momentum. Improving clinical evidence generation by evaluating the outcomes and patient experiences at the point-of-care would help achieve the ultimate aim of ensuring that effective and safe treatments are rapidly approved for patient use. In our previous publication, we assessed the global regulatory landscape with respect to RWE and provided a review of the regional availability of frameworks and guidance through May 2021 on the basis of 3 key regulatory elements: regulatory RWE frameworks, data quality guidance, and study methods guidance. In the current review, we have updated and elaborated upon recent developments in the regulatory RWE environment from a regional perspective under the same 3 regulatory elements stated above. In addition, we have also included a new category on procedural guidance. The review also discusses the perceived gaps and potential opportunities for future development and harmonization in this field to support framework establishment in regions without pre-existing RWE policies. Additionally, the article reviews current developments of health technology assessment (HTA) bodies pertaining to RWE and discusses the status of evidentiary alignment among regulators and HTA agencies.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Making Real-World Evidence More Useful for Decision Making
    Greenfield, Sheldon
    VALUE IN HEALTH, 2017, 20 (08) : 1023 - 1024
  • [22] REAL-WORLD EVIDENCE IN MULTIPLE SCLEROSIS (MS): HTA DECISION-MAKING INFLUENCER OR NOT?
    Nanda, S.
    Jindal, S.
    Rohillla, A.
    Mahajan, S.
    Saharia, P.
    VALUE IN HEALTH, 2022, 25 (12) : S344 - S344
  • [23] The evolution of real-world evidence in healthcare decision making
    Williams, David M.
    Evans, Marc
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 443 - 445
  • [24] Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making
    Alnofal, Fatemah A.
    Alrwisan, Adel A.
    Alshammari, Thamir M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (10) : 1303 - 1306
  • [25] Development of audit readiness considerations of real-world data for use in regulatory decision-making
    Atzinger, Christopher B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 411 - 411
  • [26] DECISION-MAKING IN REAL WORLD
    HOLLANDER, GL
    IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS, 1972, SMC2 (02): : 275 - +
  • [27] Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making
    Bakker, Elisabeth
    Plueschke, Kelly
    Jonker, Carla J.
    Kurz, Xavier
    Starokozhko, Viktoriia
    Mol, Peter G. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 135 - 151
  • [28] Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases
    Prilla, Stefanie
    Groeneveld, Sophie
    Pacurariu, Alexandra
    Restrepo-Mendez, Maria Clara
    Verpillat, Patrice
    Torre, Carla
    Gartner, Christian
    Mol, Peter G. M.
    Naumann-Winter, Frauke
    Breen, Kieran C.
    Gault, Nathalie
    Gross-Martirosyan, Liana
    Benchetrit, Sylvie
    Aylward, Brian
    Stoyanova-Beninska, Violeta
    O'Donovan, Maura
    Straus, Sabine
    Kjaer, Jesper
    Arlett, Peter
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024,
  • [29] CONTEXT MATTERS - A TAXONOMY OF REAL-WORLD DATA AND EVIDENCE TO SUPPORT HTA DECISION-MAKING
    Murphy, L. A.
    Mestre-Ferrandiz, J.
    Sola-Morales, O.
    de Pouvourville, G.
    Cunningham, D.
    Corry, S.
    Akehurst, R.
    VALUE IN HEALTH, 2020, 23 : S622 - S622
  • [30] Role of Real-World Evidence in Clinical Decision-Making for the Management of Advanced Prostate Cancer
    Caveney, Brian
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (03): : 152 - 154